D-serine regulatory pathway

The D-serine regulatory pathway is a complex biological system in the central nervous system responsible for the synthesis, transport, and degradation of D-serine [3, 4, 11]. D-serine serves as a primary endogenous co-agonist at the glycine modulatory site of the N-methyl-D-aspartate (NMDA) receptor, making it essential for glutamatergic neurotransmission [1, 11, 16]. The pathway's key components include the enzyme serine racemase, which converts L-serine to D-serine, and D-amino acid oxidase (DAAO), which catabolizes D-serine [3, 10, 11]. Proper regulation of this pathway is vital for synaptic plasticity, long-term potentiation, and cognitive processes such as learning and memory [1, 10, 11, 15]. Dysregulation of D-serine levels is a hallmark of several neuropsychiatric conditions; for instance, reduced D-serine is linked to NMDA receptor hypofunction in schizophrenia [1, 2, 11, 16]. Conversely, elevated D-serine levels are associated with neurotoxicity and excitotoxicity in neurodegenerative diseases like Alzheimer's and amyotrophic lateral sclerosis [2, 10, 11, 12, 15]. Therapeutic interventions targeting this pathway include direct D-serine supplementation and the use of DAAO inhibitors to elevate synaptic D-serine concentrations [1, 5, 11, 16]. Monitoring D-serine levels in the cerebrospinal fluid or serum serves as a potential biomarker for disease progression and treatment response in psychiatric disorders [1, 2, 7, 11, 14]. Safety considerations for drugs affecting this pathway include potential nephrotoxicity, as seen in high-dose animal studies, and the risk of over-activating NMDA receptors [1, 5, 6, 11].

Other names

D-serine metabolic pathwayD-serine signaling pathwayD-serine system

Modulation of NMDA receptor activity by regulating the availability of the co-agonist D-serine at the glycine modulatory site.